Moderna stock (US60770K1034): Q1 earnings beat on revenue, EPS miss sparks gains

Moderna reported Q1 2026 revenue of $389 million, up 260% year-over-year and beating estimates, though EPS of -$3.40 missed consensus. Shares rose over 11% on May 8, 2026, amid pipeline updates.

Moderna Inc. released its first-quarter 2026 earnings on May 1, 2026, posting revenue of $389 million, a 260.2% increase from $108 million a year earlier and surpassing analyst expectations of $236.37 million, MarketBeat as of 05/08/2026. Earnings per share came in at -$3.40, missing the consensus estimate of -$3.02 by $0.38. The stock surged 11.97% to close at $54.35 on May 8, 2026, on Nasdaq, with extended trading at $56.35, MarketBeat as of 05/08/2026. Moderna maintained its full-year revenue guidance at $2.1 billion.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Moderna Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: US, Europe
• Key revenue drivers: mRNA vaccines
• Home exchange/listing venue: Nasdaq (MRNA)
• Trading currency: USD

Moderna Inc.: core business model

Moderna Inc. develops and commercializes mRNA-based therapeutics and vaccines. The company focuses on modalities including prophylactic vaccines, cancer vaccines, and rare disease treatments. Its lead product, Spikevax, an mRNA COVID-19 vaccine, generated significant revenue during the pandemic. Moderna operates a platform that designs mRNA to encode proteins for immune response or therapeutic effect, company website as of 05/11/2026.

Revenue primarily stems from product sales and collaborations. In Q1 2026, sales of COVID and RSV vaccines drove the $389 million top line, per the earnings report published May 1, 2026. The firm invests heavily in R&D, with a pipeline spanning infectious diseases, oncology, and autoimmune conditions.

Main revenue and product drivers for Moderna Inc.

Key drivers include Spikevax sales and emerging vaccines like mRESVIA for RSV. Q1 2026 revenue jumped 260% year-over-year to $389 million, beating estimates by over $150 million, fueled by vaccine demand, MarketBeat as of 05/08/2026. The company reiterated 2026 revenue guidance of $2.1 billion.

Pipeline progress includes early hantavirus vaccine work, boosting shares 8% premarket recently, and positive flu vaccine data from late-stage trials on May 6, 2026, Marketscreener as of 05/11/2026. RSV and COVID products remain core, with oncology candidates in development.

Industry trends and competitive position

The biotech sector sees mRNA technology as pivotal post-COVID. Moderna competes with Pfizer-BioNTech in vaccines and leads in next-gen applications. Recent flu vaccine outperformance versus standard shots positions it strongly, per reports from May 6, 2026. Market cap stands at $21.57 billion, reflecting biotech volatility but innovation edge.

Why Moderna Inc. matters for US investors

Listed on Nasdaq, Moderna offers US investors exposure to mRNA innovation amid US healthcare spending. Its vaccines target public health priorities like flu and RSV, with significant government contracts. YTD gains of 84.30% as of recent data underscore appeal in growth-oriented portfolios, TipRanks as of 05/11/2026.

Conclusion

Moderna's Q1 2026 results highlighted revenue strength from vaccines, despite an EPS miss, driving a sharp stock rally. Pipeline advances in flu, hantavirus, and cancer bolster its biotech profile. Investors track upcoming FDA decisions and guidance execution amid sector dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.